The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 2, 2015, Pages 233-244

  Duberg, Ann Sofi ^a,b   Blach, Sarah ^c   Falconer, Karolin ^d   Kåberg, Martin ^d   Razavi, Homie ^c   Aleman, Soo ^d  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c Center for Disease Analysis   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Direct acting antiviral agents; Epidemiology; Hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Modeling; Mortality

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SIMULATION; FEMALE; GENOTYPE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH IMPACT ASSESSMENT; HEPATITIS C; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; SWEDEN; THERAPY EFFECT; ADOLESCENT; AGE DISTRIBUTION; AGED; CARCINOMA, HEPATOCELLULAR; CHILD; COHORT ANALYSIS; COST OF ILLNESS; ECONOMICS; FORECASTING; HEALTH SURVEY; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER NEOPLASMS; PREVALENCE; SEX RATIO; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHILD; COHORT STUDIES; COST OF ILLNESS; DISEASE PROGRESSION; FORECASTING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; SEX DISTRIBUTION; SWEDEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921323762     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.990505     Document Type: Article

References (52)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:74-81.
2. Duberg AS, Pettersson H, Aleman S, Blaxhult A, Daviethsdottir L, Hultcrantz R, et al. The burden of hepatitis C in Sweden: a national study of inpatient care. J Viral Hepat 2011;18:106-18.
3. Scandiatransplant. The nordic liver transplant registry. 2013. Available from http://www.scandiatransplant.org/. Cited 29 November 2013.
4. Duberg A, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill 2008;13.
5. Folkhälsomyndigheten. Public Health Agency of Sweden, Homepage, Hepatitis C statistics. 2014. Available from http: //www.folkhalsomyndigheten.se/amnesomraden/statistikoch-undersokningar/sjukdomsstatistik/hepatit-c/. Cited 27 March 2014.
6. Duberg AS, Törner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A˚, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 2008;15: 538-50.
7. Duberg A. Hepatitis C virus infection: a nationwide study of associated morbidity and mortality [Dissertation]. Örebro University; Örebro, Sweden: 2009.
8. Socialstyrelsen. The National Board of Health and Welfare; Homepage. 2014. Available from http://www.socialstyrelsen.se/english. Cited 27 March 2014.
9. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-23.
10. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
11. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r- Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014;370:1594-603.
12. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21: 60-89.
13. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21:34-59.
14. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014;21:5-33.
15. Statistics Sweden. Startpage. 2013. Available from http://www.scb.se/en-/. Cited 3 December 2013.
16. Norda R, Duberg AS, Sönnerborg A, Olcen P. Transmission of hepatitis C virus by transfusion in Orebro County, Sweden, 1990-1992. Scand J Infect Dis 1995; 27:449-52.
17. Shev S, Hermodsson S, Lindholm A, Malm E, Widell A, Norkrans G. Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors-the role of parenteral and sexual transmission. Scand J Infect Dis 1995;27: 99-104.
18. Hoffmann G, Berglund G, Elmsta˚hl S, Eriksson S, Verbaan H, Widell A, et al. Prevalence and clinical spectrum of chronic viral hepatitis in a middle- aged Swedish general urban population. Scand J Gastroenterol 2000;35: 861-5.
19. Duberg AS, Hansdotter F, How AL, Holmström A, Lesko B. [Important with generous sampling for hepatitis C after blood transfusion. The National Board of Health and Welfare's new recommendation for risk groups]. Lakartidningen 2013;110:1477-9.
20. Lidman C, Norden L, Ka˚berg M, Kall K, Franck J, Aleman S, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 2009;41:679-84.
21. Ydreborg M, Söderström A, Ha˚kanson A, Alsiö A˚, Arnholm B, Malmström P, et al. Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. Scand J Infect Dis 2011;43:522-7.
22. Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. J Clin Virol 2005;34:108-14.
23. Shev S, Widell A, Foberg U, Fryden A, Hermodsson S, Lindh G, et al. HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile. Infection 1995;23:253-7.
24. Westin J, Lindh M, Lagging LM, Norkrans G, Wejsta˚l R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis 1999;31:355-8.
25. Ma˚nsson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000;32:253-8.
26. Stenkvist J, Weiland O, Sönnerborg A, Blaxhult A, Falconer K. High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort. Scand J Infect Dis 2014;46: 624-32.
27. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
28. Lagging M, Wejsta˚l R, Uhnoo I, Gerden B, Fischler B, Friman S, et al. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis 2009;41:389-402.
29. Lagging M, Duberg AS, Wejsta˚l R, Weiland O, Lindh M, Aleman S, et al. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis 2012;44:502-21.
30. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV directacting antiviral agents: the best interferon-free combinations. Liver Int 2014;34:69-78.
31. Pawlotsky JM, New Hepatitis C. Therapies: The Toolbox, Strategies, and Challenges. Gastroenterology 2014;146: 1176-92.
32. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014;370:1604-14.
33. Ackefors M, Nystrom J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O. Evolution of fibrosis during HCV recurrence after liver transplantation-influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. J Viral Hepat 2013;20:770-8.
34. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274-87.
35. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51:388-97.
36. Syed E, Rahbin N, Weiland O, Carlsson T, Oksanen A, Birk M, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol 2008;43:1378-86.
37. Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, et al. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weightbased ribavirin. J Viral Hepat 2008;15:641-5.
38. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53:744-9.
39. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59:434-41.
40. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013;58:1918-29.
41. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
42. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in Patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-79.
43. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
44. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-93.
45. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl JMed 2014; 370:1973-82.
46. Talal AH, LaFleur J, Hoop R, Pandya P, Martin P, Jacobson I, et al. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013;37:473-81.
47. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). J Hepatol 2014;60:741-7.
48. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598-609.
49. CAN.CAN Homepage, Drugs in Sweden. 2013. Available from http://www.can.se/sv/In-English/. Cited 4 December 2013.
50. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
51. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A Risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013;57:230-6.
52. Stokkeland K, Duberg AS, Montgomery SM, Franck J, Hultcrantz R. Alcohol dependence increases the mortality risk in patients with hepatitis C. Hepatology 2013;58(S1):p. 1284A.